Abstract
Patients with chronic eosinophilic pneumonia often experience recurring disease and prolonged corticosteroid use with adverse effects. Benralizumab enabled corticosteroid discontinuation and successfully treated chronic eosinophilic pneumonia in our study, confirmed through remission induction therapy and 3-dimensional bronchial tree visualization.